Cargando…

Active8: a randomized, double-blind, placebo-controlled study of chemotherapy plus cetuximab in combination with TLR8 agonist VTX-2337 in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN)

Detalles Bibliográficos
Autores principales:	Ferris, Robert L, Cohen, Ezra, Gash, Kelly, Whiting, Sam, Manjarrez, Kristi, Dietsch, Greg, Hershberg, Robert, Bryan, James Kyle
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4288723/ http://dx.doi.org/10.1186/2051-1426-2-S3-P69

Ejemplares similares

Comparison of immune modulation by TLR8 agonist vtx-2337 (motolimod) in cancer patients and healthy volunteers
por: Dietsch, Greg, et al.
Publicado: (2014)

TLR8 agonist VTX-2337 enhances NKG2D-mediated cytotoxicity of NK cells
por: Lu, Hailing, et al.
Publicado: (2013)

Coordinated Activation of Toll-Like Receptor8 (TLR8) and NLRP3 by the TLR8 Agonist, VTX-2337, Ignites Tumoricidal Natural Killer Cell Activity
por: Dietsch, Gregory N., et al.
Publicado: (2016)

The Ultra-Potent and Selective TLR8 Agonist VTX-294 Activates Human Newborn and Adult Leukocytes
por: Dowling, David J., et al.
Publicado: (2013)

The anti-tumor effects of cetuximab in combination with VTX-2337 are T cell dependent
por: Cheng, Yinwen, et al.
Publicado: (2021)

VTX‐1463, a novel TLR‐8 agonist, attenuates nasal congestion after ragweed challenge in sensitized beagle dogs
por: Royer, Christopher M., et al.
Publicado: (2015)

A novel TLR-8 agonist attenuates nasal symptoms/congestion in both dog and human allergen challenge studies
por: Barrett, Edward G, et al.
Publicado: (2013)

Motolimod, a selective TLR8 agonist induces apoptosis in monocytic myeloid-derived suppressor cells (M-MDSC)
por: Rutnam, Zina J, et al.
Publicado: (2015)

TLR3 agonists improve the immunostimulatory potential of cetuximab against EGFR(+) head and neck cancer cells
por: Ming Lim, Chwee, et al.
Publicado: (2013)

EGFR-Targeted Therapeutics: Focus on SCCHN and NSCLC
por: Sattler, Martin, et al.
Publicado: (2008)

Cetuximab and radiation for primary and recurrent squamous cell carcinoma of the head and neck (SCCHN) in the elderly and multi-morbid patient: a single-centre experience
por: Jensen, Alexandra D, et al.
Publicado: (2010)

Trial Watch: experimental TLR7/TLR8 agonists for oncological indications
por: Frega, Giorgio, et al.
Publicado: (2020)

Development of a novel TLR8 agonist for cancer immunotherapy
por: Wang, Yuxun, et al.
Publicado: (2020)

A Phase Ib study of neoadjuvant immune biomarker modulation with cetuximab and motolimod in head and neck cancer (HNC)
por: Ferris, Robert L, et al.
Publicado: (2015)

Intratumoral immunotherapy with the TLR7/8 agonist 3M-052
por: Smirnov, DV, et al.
Publicado: (2013)

Correction to: Development of a novel TLR8 agonist for cancer immunotherapy
por: Wang, Yuxun, et al.
Publicado: (2021)

Molecular dynamics simulations reveal the selectivity mechanism of structurally similar agonists to TLR7 and TLR8
por: Wang, Xiaoyu, et al.
Publicado: (2022)

Stimulation of Innate Immune Cells by Light-Activated TLR7/8 Agonists
por: Ryu, Keun Ah, et al.
Publicado: (2014)

Rational design of antisense oligonucleotides modulating the activity of TLR7/8 agonists
por: Alharbi, Arwaf S, et al.
Publicado: (2020)

Combination of STING and TLR 7/8 Agonists as Vaccine Adjuvants for Cancer Immunotherapy
por: Bhatnagar, Shubhmita, et al.
Publicado: (2022)

Chemoradiation with Cisplatin vs. Carboplatin for Squamous Cell Carcinoma of the Head and Neck (SCCHN)
por: Rades, Dirk, et al.
Publicado: (2023)

Structure-Based Design of Human TLR8-Specific Agonists with Augmented Potency and Adjuvanticity
por: Beesu, Mallesh, et al.
Publicado: (2015)

Development of Adamantane-Conjugated TLR7/8 Agonists for Supramolecular Delivery and Cancer Immunotherapy
por: Rodell, Christopher B., et al.
Publicado: (2019)

STING and TLR7/8 agonists-based nanovaccines for synergistic antitumor immune activation
por: Zhang, Bo-Dou, et al.
Publicado: (2022)

ProLonged Liposomal Delivery of TLR7/8 Agonist for Enhanced Cancer Vaccine
por: Kim, Sehui, et al.
Publicado: (2023)

Whole genome sequence comparison of vtx2-converting phages from Enteroaggregative Haemorrhagic Escherichia coli strains
por: Grande, Laura, et al.
Publicado: (2014)

Oral Selective TLR8 Agonist Selgantolimod Induces Multiple Immune Cell Responses in Humans
por: Ayithan, Natarajan, et al.
Publicado: (2021)

T cell-independent eradication of experimental glioma by intravenous TLR7/8-agonist-loaded nanoparticles
por: Turco, Verena, et al.
Publicado: (2023)

Beyond EGFR Targeting in SCCHN: Angiogenesis, PI3K, and Other Molecular Targets
por: Saada-Bouzid, Esma, et al.
Publicado: (2019)

Concordance, Correlation, and Clinical Impact of Standardized PD-L1 and TIL Scoring in SCCHN
por: De Keukeleire, Stijn Jeroen, et al.
Publicado: (2022)

PReS-FINAL-2337: The eurofever registry: 3 years of enrollment
por: Federici, S, et al.
Publicado: (2013)

Pharmacological Activation of p53 during Human Monocyte to Macrophage Differentiation Attenuates Their Pro-Inflammatory Activation by TLR4, TLR7 and TLR8 Agonists
por: Namgaladze, Dmitry, et al.
Publicado: (2021)

TLR8: No gain, no pain
por: Barrat, Franck J.
Publicado: (2018)

Methotrexate plus or minus cetuximab as first‐line treatment in a recurrent or metastatic (R/M) squamous cell carcinoma population of the head and neck (SCCHN), unfit for cisplatin combination treatment, a phase Ib‐randomized phase II study Commence
por: Ham, Janneke C., et al.
Publicado: (2020)

A TLR7/8 agonist increases efficacy of anti-fentanyl vaccines in rodent and porcine models
por: Crouse, Bethany, et al.
Publicado: (2023)

Engineering kinetics of TLR7/8 agonist release from bottlebrush prodrugs enables tumor-focused immune stimulation
por: Bhagchandani, Sachin H., et al.
Publicado: (2023)

Phase III, randomized, open-label study of durvalumab (MEDI4736) monotherapy, or durvalumab + tremelimumab, versus standard of care (SoC), in recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): eagle
por: Ferris, Robert L, et al.
Publicado: (2015)

TLR7/8-agonist-loaded nanoparticles promote the polarization of tumour-associated macrophages to enhance cancer immunotherapy
por: Rodell, Christopher B., et al.
Publicado: (2018)

The TLR7/8 agonist R848 remodels tumor and host responses to promote survival in pancreatic cancer
por: Michaelis, Katherine A., et al.
Publicado: (2019)

Selected TLR7/8 agonist and type I interferon (IFN-α) cooperatively redefine the microglia transcriptome
por: Khatun, Mst Reshma, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_83d7t0vu6q6606mv5ulchsss3a